马拉利西巴治疗Alagille综合征患者的无事件生存率与GALA真实世界队列的比较
本研究将马拉利西巴试验中84例Alagille综合征患者最长6年的结局与GALA研究中经筛选对齐的469例真实世界队列进行比较,采用Cox比例风险模型分析无事件生存率。结果显示马拉利西巴队列的无事件生存率显著优于GALA队列(HR 0.305,95%CI 0.189-0.491,p<0.0001),提示马拉利西巴可改善Alagille综合征患者的无事件生存。
要点
- 马拉利西巴队列无事件生存率显著优于GALA队列(HR 0.305,95%CI 0.189-0.491,p<0.0001)。
- 两组年龄、总胆红素、γ-谷氨酰转移酶和丙氨酸氨基转移酶均衡,无统计学差异。
- 多项敏感性和亚组分析(包括血清胆汁酸可及性)显示相似结果。
核心结论
- 与真实世界自然史数据比较提示马拉利西巴改善Alagille综合征患者的无事件生存率。
- 本研究展示了一种稳健统计方法在无法进行安慰剂对照的长期干预研究中的新应用,为罕见病提供广泛适用性。
研究设计与样本
- 马拉利西巴试验纳入84例Alagille综合征患者,治疗最长6年。
- GALA研究包含1438例参与者的回顾性数据,经关键马拉利西巴入选标准筛选后得到469例参与者。
- 血清胆汁酸未纳入GALA筛选标准,因临床实践中不常规检测。
- 通过最大似然估计确定索引时间,以对齐两队列疾病严重程度与马拉利西巴起始时间。
主要发现
- 马拉利西巴队列无事件生存率显著优于GALA队列(HR 0.305,95%CI 0.189-0.491,p<0.0001)。
- 年龄、总胆红素、γ-谷氨酰转移酶和丙氨酸氨基转移酶在两组间均衡,无统计学差异。
- 多项敏感性和亚组分析(包括血清胆汁酸可及性)显示相似结果。
关键数值与推荐
- 无事件生存定义为至首次发生门静脉高压表现(静脉曲张出血、需治疗的腹水)、手术胆道分流、肝移植或死亡的时间。
- 采用Cox比例风险方法分析无事件生存率,并应用敏感性分析和协变量调整。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Alagille syndrome (ALGS) is characterized by chronic cholestasis with associated pruritus and extrahepatic anomalies. Maralixibat, an ileal bile acid transporter inhibitor, is an approved pharmacologic therapy for cholestatic pruritus in ALGS. Since long-term placebo-controlled studies are not feasible or ethical in children with rare diseases, a novel approach was taken comparing 6-year outcomes from maralixibat trials with an aligned and harmonized natural history cohort from the G lobal AL agille A lliance (GALA) study. APPROACH AND RESULTS: Maralixibat trials comprise 84 patients with ALGS with up to 6 years of treatment. GALA contains retrospective data from 1438 participants. GALA was filtered to align with key maralixibat eligibility criteria, yielding 469 participants. Serum bile acids could not be included in the GALA filtering criteria as these are not routinely performed in clinical practice. Index time was determined through maximum likelihood estimation in an effort to align the disease severity between the two cohorts with the initiation of maralixibat. Event-free survival, defined as the time to first event of manifestations of portal hypertension (variceal bleeding, ascites requiring therapy), surgical biliary diversion, liver transplant, or death, was analyzed by Cox proportional hazards methods. Sensitivity analyses and adjustments for covariates were applied. Age, total bilirubin, gamma-glutamyl transferase, and alanine aminotransferase were balanced between groups with no statistical differences. Event-free survival in the maralixibat cohort was significantly better than the GALA cohort (HR, 0.305; 95% CI, 0.189-0.491; p <0.0001). Multiple sensitivity and subgroup analyses (including serum bile acid availability) showed similar findings. CONCLUSIONS: This study demonstrates a novel application of a robust statistical method to evaluate outcomes in long-term intervention studies where placebo comparisons are not feasible, providing wide application for rare diseases. This comparison with real-world natural history data suggests that maralixibat improves event-free survival in patients with ALGS.
引用
- Hansen BE, Vandriel SM, Vig P, et al. Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA. Hepatology. 2023. PMID: 38146932. doi:10.1097/HEP.0000000000000727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。